Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma
暂无分享,去创建一个
T. Cloughesy | A. Lai | L. Nghiemphu | B. Jiang | B. Ellingson | Hyun J. Kim | A. Sepahdari | M. Linetsky | Xin J. Qiao | Danny J.J. Wang | N. Salamon | J. J. Tian | Shannon R. Esswein | W. B. Pope
[1] G. Zaharchuk,et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. , 2015, Magnetic resonance in medicine.
[2] R. Pallini,et al. Is deferred use of bevacizumab for glioblastoma associated with prolonged survival? , 2014, Neuro-oncology.
[3] W. Mueller,et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.
[4] Seung Hong Choi,et al. Grading of Cerebral Glioma with Multiparametric MR Imaging and 18F-FDG-PET: Concordance and Accuracy , 2014, European Radiology.
[5] Maria I. Argyropoulou,et al. Correlation of diffusion tensor, dynamic susceptibility contrast MRI and 99mTc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma , 2014, Clinical Neurology and Neurosurgery.
[6] Whitney B. Pope,et al. Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke — Comparison with dynamic susceptibility contrast enhanced perfusion imaging☆ , 2013, NeuroImage: Clinical.
[7] P. LaViolette,et al. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. , 2013, Neuro-oncology.
[8] Ryan A. Grant,et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. , 2012, Neuro-oncology.
[9] Whitney B. Pope,et al. The Value of Arterial Spin-Labeled Perfusion Imaging in Acute Ischemic Stroke: Comparison With Dynamic Susceptibility Contrast-Enhanced MRI , 2012, Stroke.
[10] J. Debbins,et al. Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma , 2012, American Journal of Neuroradiology.
[11] Bram Stieltjes,et al. Biopsy Targeting Gliomas: Do Functional Imaging Techniques Identify Similar Target Areas? , 2010, Investigative radiology.
[12] Erwin G. Van Meir,et al. Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma , 2010, CA: a cancer journal for clinicians.
[13] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Kaye,et al. The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.
[15] H. R. Arvinda,et al. Retraction Note to: Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging , 2009, Journal of Neuro-Oncology.
[16] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[17] T Sasaki,et al. Perfusion Imaging of Brain Tumors Using Arterial Spin-Labeling: Correlation with Histopathologic Vascular Density , 2008, American Journal of Neuroradiology.
[18] S. Horvath,et al. Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples , 2008, Clinical Cancer Research.
[19] E. Melhem,et al. Arterial Spin-Labeling and MR Spectroscopy in the Differentiation of Gliomas , 2007, American Journal of Neuroradiology.
[20] S. Y. Kim,et al. A Prospective Study on the Added Value of Pulsed Arterial Spin-Labeling and Apparent Diffusion Coefficients in the Grading of Gliomas , 2007, American Journal of Neuroradiology.
[21] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[22] Li Zhang,et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[24] J. Raizer. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme , 2005, Journal of Neuro-Oncology.
[25] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[26] D. O’Rourke,et al. SHP-2-Dependent Mitogen-Activated Protein Kinase Activation Regulates EGFRvIII but not Wild-Type Epidermal Growth Factor Receptor Phosphorylation and Glioblastoma Cell Survival , 2004, Cancer Research.
[27] Glyn Johnson,et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.
[28] Joseph A Maldjian,et al. Arterial transit time imaging with flow encoding arterial spin tagging (FEAST) , 2003, Magnetic resonance in medicine.
[29] C. Zimmer,et al. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. , 2003, Radiology.
[30] D. Louis,et al. Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.
[31] A Guha,et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.
[32] W. Cavenee,et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Cloughesy,et al. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. , 2014, Neuro-oncology.
[34] S. Ekholm,et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes , 2013, Journal of Neuro-Oncology.
[35] Mei-Yin Polley,et al. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.
[36] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.